España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Blueprint Medicines
BPMC
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Blueprint Medicines (BPMC) Forecast
News
Earnings
Blueprint Medicines (BPMC) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Blueprint Medicines (NASDAQ:BPMC) Stock
Blueprint Medicines Stock (NASDAQ: BPMC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 27, 2025
Analyst Expectations For Blueprint Medicines's Future
Benzinga Insights
Piper Sandler Maintains Neutral on Blueprint ...
Benzinga Newsdesk
Sunday, January 19, 2025
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Lekha Gupta
Wednesday, January 15, 2025
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Monday, January 13, 2025
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Blueprint Medicines shares are trading higher...
Benzinga Newsdesk
Wedbush Reiterates Outperform on Blueprint Me...
Benzinga Newsdesk
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Reported Earlier, Blueprint Medicines Sees AY...
Benzinga Newsdesk
Thursday, January 02, 2025
What Analysts Are Saying About Blueprint Medicines Stock
Benzinga Insights
Stephens & Co. Reiterates Overweight on Bluep...
Benzinga Newsdesk
Wednesday, December 11, 2024
Guggenheim Reiterates Buy on Blueprint Medici...
Benzinga Newsdesk
Monday, December 09, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Reported Saturday, Blueprint Medicines Showca...
Benzinga Newsdesk
Monday, November 18, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, November 15, 2024
HC Wainwright & Co. Reiterates Buy on Bluepri...
Benzinga Newsdesk
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Thursday, November 14, 2024
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
Vandana Singh
Key Takeaways From Blueprint Medicines Analyst Ratings
Benzinga Insights
JP Morgan Initiates Coverage On Blueprint Med...
Benzinga Newsdesk
Thursday, October 31, 2024
Wells Fargo Maintains Overweight on Blueprint...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Bluepri...
Benzinga Newsdesk
Needham Maintains Buy on Blueprint Medicines,...
Benzinga Newsdesk
Wednesday, October 30, 2024
Blueprint Medicines shares are trading higher...
Benzinga Newsdesk
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Blueprint Medicines Expects 2024 Ayvakit Net ...
Benzinga Newsdesk
Blueprint Medicines Q3 2024 GAAP EPS $(0.89) ...
Benzinga Newsdesk
Thursday, October 24, 2024
Analyst Ratings For Blueprint Medicines
Benzinga Insights
UBS Initiates Coverage On Blueprint Medicines...
Benzinga Newsdesk
Tuesday, August 13, 2024
9 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, August 08, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Monday, August 05, 2024
Needham Maintains Buy on Blueprint Medicines,...
Benzinga Newsdesk
Friday, August 02, 2024
Guggenheim Maintains Buy on Blueprint Medicin...
Benzinga Newsdesk
Baird Maintains Outperform on Blueprint Medic...
Benzinga Newsdesk
Thursday, August 01, 2024
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Blueprint Medicines Continues To Expect That ...
Benzinga Newsdesk
Blueprint Medicines Corp Raised 2024 Global A...
Benzinga Newsdesk
Blueprint Medicines Q2 2024 GAAP EPS $(0.80) ...
Benzinga Newsdesk
Tuesday, July 30, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Monday, July 29, 2024
15 Analysts Have This To Say About Blueprint Medicines
Benzinga Insights
Barclays Maintains Equal-Weight on Blueprint ...
Benzinga Newsdesk
Friday, July 12, 2024
Morgan Stanley Maintains Equal-Weight on Blue...
Benzinga Newsdesk
Monday, July 08, 2024
Oppenheimer Maintains Outperform on Blueprint...
Benzinga Newsdesk
Friday, June 28, 2024
Expert Ratings For Blueprint Medicines
Benzinga Insights
Needham Reiterates Buy on Blueprint Medicines...
Benzinga Newsdesk
Friday, June 07, 2024
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Benzinga Insights
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, May 17, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Tuesday, May 14, 2024
Unveiling 18 Analyst Insights On Blueprint Medicines
Benzinga Insights
Stephens & Co. Initiates Coverage On Blueprin...
Benzinga Newsdesk
Show More
